Should Cystatin C eGFR Become Routine Clinical Practice?

Area of Science:

• Nephrology
• Biomarker Discovery
• Clinical Chemistry

Background:

• Kidney function assessment is vital for managing kidney diseases.
• Glomerular filtration rate (GFR) is a key indicator, but direct measurement is difficult.
• Serum creatinine is a common but limited marker for estimating GFR (eGFR).

Purpose of the Study:

• To evaluate cystatin C as a superior alternative marker for kidney function assessment.
• To compare the accuracy and predictive value of cystatin C-based eGFR with creatinine-based eGFR.
• To explore the utility of combined creatinine-cystatin C equations for eGFR estimation.

Main Methods:

• Review of studies comparing cystatin C and creatinine for GFR estimation.
• Analysis of various eGFR equations, including CKD-EPI_creat-cys.
• Assessment of predictive performance for clinical outcomes and risk stratification.

Main Results:

• Cystatin C is less influenced by non-kidney factors like muscle mass compared to creatinine.
• The CKD-EPI_creat-cys equation shows improved accuracy, particularly in specific eGFR ranges.
• Cystatin C-based eGFR demonstrates superior prediction of clinical outcomes and patient risk, especially in diverse populations.

Conclusions:

• Cystatin C offers significant advantages over creatinine for kidney function assessment.
• Routine use of cystatin C can enhance early kidney disease detection and patient risk stratification.
• Wider adoption requires improved laboratory accessibility and further implementation research.